ArticleWorld journal of gastrointestinal endoscopy2025
Feasibility and safety of endoscopic ultrasound-guided liver biopsy to diagnose parenchymal liver disease: A multi-centre retrospective cohort study.
Article in World journal of gastrointestinal endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endoscopic ultrasound-guided liver biopsy: Are we ready for routine use?World journal of gastrointestinal endoscopy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver biopsy is an important diagnostic tool to investigate patients with suspected liver disease. The efficacy and safety of endoscopic ultrasound-guided liver biopsy (EUS-LB) as a method for liver tissue acquisition remain uncertain.
aimTo study the diagnostic yield and safety of EUS-LB in patients with suspected parenchymal liver disease.
methodsThis is a retrospective observational cohort study of patients undergoing EUS-LB in 2 tertiary-care centers in Kuwait in the period between January 2022-June 2025. The primary outcome was sample adequacy, while secondary outcomes included histological quality of the specimen and adverse events. Predictors of increased diagnostic adequacy and specimen quality were explored.
resultsA total of 50 patients [mean age 43.9 (15.5) years, 40% males] were included. The left liver lobe was targeted for biopsy in most patients (96%), and 19-gauge fine needle aspiration (FNA) was used in most cases (52%). The median number of passes performed was 3 (range 2-5), and the heparin-wet suction technique was used in 40% of patients. The overall diagnostic adequacy of EUS-LB was 86%, with no significant difference between 19-gauge FNA and 19-gauge fine needle biopsy (FNB) needles. Fulfillment of the European Association for the Study of Liver (EASL) and the American Association for the Study of Liver Diseases criteria was achieved in 54% and 34%, respectively, with a significantly higher number of patients fulfilling these criteria when FNB needle was used compared to FNA needle (83.3%
conclusionEUS-LB is an effective and safe method for obtaining liver biopsy in patients with suspected parenchymal liver disease. EUS-LB demonstrated a favorable safety profile in our cohort, although larger prospective studies are required to validate bleeding risk. The use of 19-gauge FNB needles, wet-heparin suction technique, and performing ≤ 2 passes is associated with improved quality of the specimen obtained without increasing the risk of adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.